益生菌在重症急性胰腺炎相关性肺损伤治疗中的研究进展  

Research progress of probiotics in the treatment of severe acute pancreatitis-associated lung injury

作　　者：郭若琳 尹毅霞[1] 王荣[1] 罗永 GUO Ruolin;YIN Yixia;WANG Rong;LUO Yong(Youjiang Medical University for Nationalities,Guangxi,Baise 533000,China)

机构地区：[1]右江民族医学院,广西百色533000

出　　处：《中国医药科学》2025年第2期20-23,65,共5页China Medicine And Pharmacy

基　　金：广西壮族自治区研究生教育创新计划项目(YCSW2023509);广西肝胆疾病临床医学研究中心研究课题(桂科AD17129025-49);广西壮族自治区卫生厅科研课题(Z2013779)。

摘　　要：重症急性胰腺炎相关性肺损伤(SAP-LI)是急性胰腺炎的早期并发症,早期即出现肠道菌群改变。因肠道-肺“双向通信”的存在,肠道菌群及其代谢产物导致炎症因子大量释放,进一步加重了肺组织的损伤。益生菌在临床上用于多种危重疾病的肠道屏障功能保护治疗,减少肠道致病菌经血液循环及淋巴途径等易位至肺脏,抑制炎症因子的释放,对减少肺损伤提供了极大的帮助。本文就SAP-LI发病的病理生理机制、益生菌生物学作用、益生菌对肠道菌群平衡、肠道-肺轴、免疫调节的影响,及益生菌对SAP-LI治疗的潜在作用进行综述。Severe acute pancreatitis-associated lung injury(SAP-LI)is an early complication of acute pancreatitis,characterized by changes in gut microbiota in the early stages.Due to the bidirectional communication between the intestine and lungs,intestinal bacteria and their metabolites lead to the release of a large number of inflammatory factors,further exacerbating lung tissue damage.Probiotics are used in clinical practice for the protection and treatment of intestinal barrier function in various critical diseases,reducing the translocation of intestinal pathogenic bacteria to the lungs through blood circulation and lymphatic pathways,inhibiting the release of inflammatory factors,and providing great help in reducing lung injury.This article reviews the pathophysiological mechanisms of SAP-LI,the biological effects of probiotics,the impact of probiotics on gut microbiota balance,the gut lung axis,immune regulation,and the potential role of probiotics in SAP-LI treatment.

关 键 词：重症急性胰腺炎 肺损伤 发病机制 益生菌 疗效 

分 类 号：R576[医药卫生—消化系统]